Clinical Scorecard: Initial Insights on Targeted and Combination Biopsy Techniques for Prostate Cancer Evaluation in Denmark (2012-2016)

At a Glance

Key Highlights

• Combination biopsy (cBx) shows higher concordance with radical prostatectomy pathology than targeted (tBx) or systematic biopsy (sBx) alone.
• cBx had moderate agreement between tBx and sBx components (weighted kappa 0.67), with 54% unchanged Gleason grade from biopsy to prostatectomy.
• Prostate cancer-specific mortality at 6 years was 0% for non-malignant or Gleason grade 1, increasing with higher Gleason grades across biopsy methods.

Guideline-Based Recommendations

Diagnosis

• Incorporate MRI to guide targeted biopsies to reduce unnecessary biopsies.
• Use combination biopsy (cBx) to improve detection of clinically significant prostate cancer compared to standalone systematic biopsy.

Management

• Consider biopsy Gleason grading concordance with prostatectomy pathology when planning treatment.
• Monitor patients with Gleason grade 1 or non-malignant biopsy results closely given low prostate cancer-specific mortality.

Monitoring & Follow-up

• Follow patients longitudinally with attention to Gleason grade changes from biopsy to prostatectomy.
• Use prostate cancer-specific death rates stratified by Gleason grade to inform prognosis and follow-up intensity.

Risks

• Targeted biopsy alone may lead to overgrading and potential overtreatment.
• Standalone systematic biopsy shows lower concordance with prostatectomy pathology and may miss clinically significant cancers.

Patient & Prescribing Data

Men undergoing first prostate biopsy in Denmark (2012-2016), including those treated with radical prostatectomy.

Combination biopsy improves diagnostic accuracy and grading concordance, supporting its use over standalone systematic biopsy.

Clinical Best Practices

• Utilize MRI to guide targeted biopsy to reduce unnecessary procedures.
• Perform combination biopsy (targeted plus systematic) to maximize detection of clinically significant prostate cancer.
• Interpret biopsy Gleason grade with caution, considering potential upgrading or downgrading at prostatectomy.
• Use biopsy Gleason grade to stratify patient risk and guide follow-up and treatment decisions.

References

• Reference 1 - MRI advancement in prostate cancer diagnosis
• References 2-5 - Discussions on targeted biopsy overgrading and overtreatment
• References 6-7 - Combination biopsy detection rates
• Reference 8 - Danish Prostate Cancer Registry (DaPCaR2)
• Reference 9 - National patient registry MRI data
• Reference 10 - Weighted Cohen’s kappa statistical method